The Antibody Drug Conjugate, Belantamab-Mafodotin, in the Treatment of Multiple Myeloma: A Comprehensive Review
Introduction Multiple myeloma (MM), the second most prevalent hematological malignancy, accounts for 1% of all cancers.1,2 It is marked by the proliferation of malignant plasma cells, resulting in their accumulation in the bone marrow and the …